The long-term treatment of restless legs syndrome/Willis–Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
The Executive Committee of the International Restless Legs Syndrome Study Group (IRLSSG) decided two years ago to create two a task force to perform an evidence-based review of the long-term efficacy and toxicity of RLS treatments. The main reason was that long-term treatment of this disorder has specific problems that may affect efficacy and are normally not addressed in shorter studies.
In addition, the task force considered it important to come to a consensus and establish recommendations based on experienced on those issues where no specific data were available. The results of this were presented and approved at the annual IRLSSG Meeting in Boston 2012 and were shown on our web page as Summary Recommendations for the long-Term Treatment of RLS/Willis-Ekbom disease.
In the meantime, the full manuscript has been peer reviewed and published in Sleep Medicine where it can be freely downloaded at the www.irlssg.org website. The report contains important recommendations such as which treatment to start first and when, how to manage loss of efficacy and augmentation, and how to handle the main side effects of long-term treatment.